Targeting 3D Bladder Cancer Spheroids with Urease-Powered Nanomotors
Source abstract
Abstract
Cancer is one of the main causes of death around the world, lacking efficient clinical treatments that generally present severe side effects. In recent years, various nanosystems have been explored to specifically target tumor tissues, enhancing the efficacy of cancer treatment and minimizing the side effects. In particular, bladder cancer is the ninth most common cancer worldwide and presents a high survival rate but serious recurrence levels, demanding an improvement in the existent therapies. Here, we present urease-powered nanomotors based on mesoporous silica nanoparticles that contain both polyethylene glycol and anti-FGFR3 antibody on their outer surface to target bladder cancer cells in the form of 3D spheroids. The autonomous motion is promoted by urea, which acts as fuel and is inherently present at high concentrations in the bladder. Antibody-modified nanomotors were able to swim in both simulated and real urine, showing a substrate-dependent enhanced diffusion. The internalization efficiency of the antibody-modified nanomotors into the spheroids in the presence of urea was significantly higher compared with antibody-modified passive particles or bare nanomotors. Furthermore, targeted nanomotors resulted in a higher suppression of spheroid proliferation compared with bare nanomotors, which could arise from the local ammonia production and the therapeutic effect of anti-FGFR3. These results hold significant potential for the development of improved targeted cancer therapy and diagnostics using biocompatible nanomotors.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Micro and Nano Robotics · Genetic and Kidney Cyst Diseases · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology (BIST), Baldiri i Reixac 10-12, 08028 Barcelona Spain
Institució Catalana de Recerca i Estudis Avancats (ICREA), Passeig Lluís Companys 23, 08010 Barcelona, Spain
Funding
Fundaci?n BBVA · Secretar?a de Estado de Investigaci?n, Desarrollo e Innovaci?n · Generalitat de Catalunya
References (68)
Show source-provided references
1. Ferlay J.
2. 10.1038/nrc.2016.10810.1038/nrc.2016.108 ↗
3. 10.1038/nrc156610.1038/nrc1566 ↗
4. Mirkin C. A. · 2015 · 16610.1007/978-3-319-16555-4 ↗
5. 10.1038/natrevmats.2016.1410.1038/natrevmats.2016.14 ↗
6. 10.1038/nbt.333010.1038/nbt.3330 ↗
7. 10.1039/C6CC09169E10.1039/C6CC09169E ↗
8. 10.1021/nn302899710.1021/nn3028997 ↗
9. 10.1039/C7NR05535H10.1039/C7NR05535H ↗
10. 10.1002/adfm.20170508610.1002/adfm.201705086 ↗
11. 10.1126/scirobotics.aam643110.1126/scirobotics.aam6431 ↗
12. 10.1021/acsami.8b0577610.1021/acsami.8b05776 ↗
13. 10.1002/anie.20180345710.1002/anie.201803457 ↗
14. 10.1002/adfm.20170586210.1002/adfm.201705862 ↗
15. 10.1002/anie.20180191010.1002/anie.201801910 ↗
16. 10.1021/acsnano.7b0192610.1021/acsnano.7b01926 ↗
17. 10.1002/anie.20171308210.1002/anie.201713082 ↗
18. 10.1016/j.apmt.2017.04.00610.1016/j.apmt.2017.04.006 ↗
19. 10.1021/acs.nanolett.7b0238310.1021/acs.nanolett.7b02383 ↗
20. 10.1126/sciadv.150050110.1126/sciadv.1500501 ↗
21. 10.1021/acs.nanolett.5b0422110.1021/acs.nanolett.5b04221 ↗
22. 10.1073/pnas.091042610710.1073/pnas.0910426107 ↗
23. 10.1002/admi.20150050510.1002/admi.201500505 ↗
24. 10.1002/advs.20170005810.1002/advs.201700058 ↗
25. 10.1002/smll.20160367910.1002/smll.201603679 ↗
26. 10.1177/027836490810092410.1177/0278364908100924 ↗
27. 10.1021/acsnano.7b0412810.1021/acsnano.7b04128 ↗
28. 10.1038/nnano.2016.13710.1038/nnano.2016.137 ↗
29. 10.1002/anie.20140609610.1002/anie.201406096 ↗
30. 10.1021/acsnano.6b0410810.1021/acsnano.6b04108 ↗
31. 10.1021/acs.accounts.6b0038610.1021/acs.accounts.6b00386 ↗
32. 10.1002/anie.20130861010.1002/anie.201308610 ↗
33. 10.1021/nn204762w10.1021/nn204762w ↗
34. 10.1002/adfm.20090237610.1002/adfm.200902376 ↗
35. 10.1038/s41467-017-00309-w10.1038/s41467-017-00309-w ↗
36. 10.1021/acsnano.8b0376010.1021/acsnano.8b03760 ↗
37. 10.1021/acs.nanolett.5b0310010.1021/acs.nanolett.5b03100 ↗
38. 10.1021/acsnano.5b0806710.1021/acsnano.5b08067 ↗
39. 10.1021/acscentsci.6b0025410.1021/acscentsci.6b00254 ↗
40. 10.1021/acsnano.5b0768910.1021/acsnano.5b07689 ↗
41. 10.1021/acs.accounts.8b0028810.1021/acs.accounts.8b00288 ↗
42. 10.1021/acs.accounts.8b0028610.1021/acs.accounts.8b00286 ↗
43. 10.1038/s41929-018-0053-110.1038/s41929-018-0053-1 ↗
44. 10.1016/j.bios.2014.05.06210.1016/j.bios.2014.05.062 ↗
45. 10.1021/jacs.8b0346010.1021/jacs.8b03460 ↗
46. 10.1021/acs.nanolett.5b0393510.1021/acs.nanolett.5b03935 ↗
47. 10.1126/sciadv.170036210.1126/sciadv.1700362 ↗
48. 10.1021/jacs.6b0685710.1021/jacs.6b06857 ↗
49. 10.1039/C2AN15780B10.1039/C2AN15780B ↗
50. 10.1016/j.eururo.2016.06.01010.1016/j.eururo.2016.06.010 ↗
51. 10.1038/551S34a10.1038/551S34a ↗
52. Janicki J. J. · Transl. Androl. Urol. Vol 4, No 5 (October 2015) Transl. Androl. Urol. (Interstitial Cystitis/Painful Bl. Syndr. Part I) · 2015 · 5 · 572
53. 10.1021/mp060001j10.1021/mp060001j ↗
54. 10.1089/adt.2014.57310.1089/adt.2014.573 ↗
55. 10.1158/1078-0432.CCR-05-028210.1158/1078-0432.CCR-05-0282 ↗
56. 10.1016/j.urolonc.2011.12.00110.1016/j.urolonc.2011.12.001 ↗
57. 10.1002/cam4.26210.1002/cam4.262 ↗
58. 10.1172/JCI3801710.1172/JCI38017 ↗
59. 10.1172/JCI3894810.1172/JCI38948 ↗
60. 10.1039/b302404k10.1039/b302404k ↗
61. 10.1007/s11051-012-1293-710.1007/s11051-012-1293-7 ↗
62. 10.1016/j.sbsr.2016.04.00210.1016/j.sbsr.2016.04.002 ↗
63. 10.1016/0003-2697(85)90442-710.1016/0003-2697(85)90442-7 ↗
64. 10.1103/PhysRevLett.99.04810210.1103/PhysRevLett.99.048102 ↗
65. 10.1021/la301370y10.1021/la301370y ↗
66. Elia N. · 2009 · 43 · 4.22.1
67. ISO · 2016
68. 10.1021/ac50011a03410.1021/ac50011a034 ↗